FlandersBio on Twitter

Follow us on Twitter

Archive for October 2011 - News

Archive for October 2011 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

Cryo-Save launches educational program on clinical applications of stem cell therapies


Cryo-Save, Europe’s leading family stem cell bank launches an educational program on stem cell therapies. The aim of the program is to increase the awareness of stem cells therapy and regenerative medicine amongst healthcare professionals. Cryo-Save Serbia played a lead role in coordinating this annual event on Regenerative Medicine, Tissue and Genetic Engineering in Belgrade, Serbia earlier this October. read more

MDxHealth Epigenetic Biomarkers Show Ability to Confirm the Presence of Lung Cancer in Sputum Samples


MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced the results of a study indicating that several of its epigenetic biomarkers are able to confirm the presence of non-small cell lung cancer (NSCLC) from routinely collected sputum samples of patients with stages I-IV of the disease. MDxHealth is developing a molecular diagnostic test, ConfirmMDx for Lung CancerTM, to help physicians accurately assess the presence or absence of cancer genes. These important new data will be presented at the 5th EORTC - NCI - ASCO Annual Meeting on Molecular Markers in Cancer in Brussels, Belgium (October 27-29) read more

UC Davis European Plant Breeding AcademySM starts the second class


Contributing to fill a critical need for trained plant breeders, the University of California, Davis European Plant Breeding AcademySM (EPBA) started its second class of students this week. Over the next two years, during the six sessions held in Gent, Belgium; Angers, France; Gatersleben, Germany; Enkhuizen, The Netherlands; Barcelona, Spain, and UC Davis; this class will spend more than 300 hours in classes, workshops and the field, training to become professional plant breeders. read more

Complix selects first Alphabody™ development candidate


Complix NV, a biopharmaceutical company focused on the discovery and development of Alphabodies™, a novel class of protein therapeutics, announced today that it has progressed its first Alphabody™ product, CMPX-1023, into preclinical development. CMPX-1023 is under development for treatment of autoimmune diseases and inflammation. Complix has achieved this important milestone less than 12 months after starting the discovery program for this compound, illustrating the efficiency of its proprietary Alphabody™ discovery engine. CMPX-1023 is Complix´s first Alphabody™ entering the development phase. Complix has other ongoing discovery programs for Alphabody™ therapeutics against autoimmune and viral diseases. read more

TiGenix rheumatoid arthritis Phase IIa study moves into randomized recruitment


TiGenix (NYSE Euronext: TIG) announced today that it has received the go-ahead from the independent Safety Monitoring Board to move into the randomized stage of the company's Phase IIa clinical trial in rheumatoid arthritis (Cx611). This decision is based on the analysis of the safety data from patients treated in the study's first cohort. read more

ERC awards 2000th grant to researcher VIB-K.U.Leuven Matthew Holt


The European Research Council (ERC) has awarded its 2000th ERC grant to Matthew Holt, a British neuroscientist who will start in early 2012 at VIB-K.U.Leuven. The ERC Starting Grant, almost €1.5 million, is one of the most prestigious grants for young researchers in the European Union. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top